Staurosporine derivatives for hypereosinophilic syndrome

Details Staurosporine derivatives for hypereosinophilic syndrome Staurosporine derivatives for hypereosinophilic syndrome

A - Human Necessities

61

K

A61K 31/404 (2006.01) A61P 7/00 (2006.01) A61P 11/00 (2006.01) A61P 43/00 (2006.01)

Patent

CA 2528156

The present invention relates to the use of staurosporine derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFR.alpha.-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, or other diseases associated with FIPL1-PDGFRa or similar mutations that activate PDGFR.alpha..

La présente invention concerne l'utilisation de dérivés de staurosporine dans la préparation d'un médicament pour le traitement de maladies myéloprolifératives induites par FIP1L1-PDGFR.alpha., notamment pour le traitement curatif et/ou prophylactique du syndrome hyperéosinophile et le syndrome hyperéosinophile à résistance à l'imatinib, ainsi qu'une méthode de traitement du syndrome hyperéosinophile et du syndrome hyperéosinophile à résistance à l'imatinib, ou d'autres maladies associées à FIPL1-PDGFRa ou des mutations similaires activant le PDGFR.alpha..

Affiliated with

Also associated with

Rating

Staurosporine derivatives for hypereosinophilic syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Staurosporine derivatives for hypereosinophilic syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Staurosporine derivatives for hypereosinophilic syndrome will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2074472